These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1866375)

  • 1. Bioavailability of flurbiprofen following buccal administration.
    Stalker DJ; Pollock SR
    Pharm Res; 1991 May; 8(5):605-7. PubMed ID: 1866375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human buccal absorption of flurbiprofen.
    Barsuhn CL; Olanoff LS; Gleason DD; Adkins EL; Ho NF
    Clin Pharmacol Ther; 1988 Aug; 44(2):225-31. PubMed ID: 3293876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption of flurbiprofen through human buccal mucosa.
    Gonzalez-Younes I; Wagner JG; Gaines DA; Ferry JJ; Hageman JM
    J Pharm Sci; 1991 Sep; 80(9):820-3. PubMed ID: 1800701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the oral dissolution time on the absorption rate of locally administered solid formulations for oromucosal use: the flurbiprofen lozenges paradigm.
    Imberti R; De Gregori S; Lisi L; Navarra P
    Pharmacology; 2014; 94(3-4):143-7. PubMed ID: 25277061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple dosing increases the ocular bioavailability of topically administered flurbiprofen.
    Anderson JA; Chen CC
    Arch Ophthalmol; 1988 Aug; 106(8):1107-9. PubMed ID: 3401139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, two-period, cross-over, open-label study to evaluate the pharmacokinetic profiles of single doses of two different flurbiprofen 8.75-mg lozenges in healthy volunteers.
    Matzneller P; Burian A; Martin W; Annoni O; Lauro V; Tacchi R; Brunner M; Zeitlinger M
    Pharmacology; 2012; 89(3-4):188-91. PubMed ID: 22433300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the bioavailability of flurbiprofen and its beta-cyclodextrin inclusion complex in four different doses upon oral administration to rats.
    Muraoka A; Tokumura T; Machida Y
    Eur J Pharm Biopharm; 2004 Nov; 58(3):667-71. PubMed ID: 15451543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations.
    Pargal A; Kelkar MG; Nayak PJ
    Biopharm Drug Dispos; 1996 Aug; 17(6):511-9. PubMed ID: 8866042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic comparison of oral and local action transcutaneous flurbiprofen in healthy volunteers.
    Taburet AM; Singlas E; Glass RC; Thomas F; Leutenegger E
    J Clin Pharm Ther; 1995 Apr; 20(2):101-7. PubMed ID: 7650070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dual-reverse thermosensitive solid lipid nanoparticle-loaded hydrogel for rectal administration of flurbiprofen with improved bioavailability and reduced initial burst effect.
    Din FU; Mustapha O; Kim DW; Rashid R; Park JH; Choi JY; Ku SK; Yong CS; Kim JO; Choi HG
    Eur J Pharm Biopharm; 2015 Aug; 94():64-72. PubMed ID: 25979136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of two flurbiprofen products: stereospecific versus conventional approach.
    Jamali F; Collins DS; Berry BW; Molder S; Cheung R; McColl K; Cheung H
    Biopharm Drug Dispos; 1991; 12(6):435-45. PubMed ID: 1932607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of flurbiprofen.
    Kaiser DG; Brooks CD; Lomen PL
    Am J Med; 1986 Mar; 80(3A):10-5. PubMed ID: 3963013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of flurbiprofen in rheumatoid patients receiving flurbiprofen over long periods of time.
    Cardoe N; de-Silva M; Glass RC; Risdall PC
    Curr Med Res Opin; 1977; 5(1):21-5. PubMed ID: 913119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect.
    Sonvico F; Conti C; Colombo G; Buttini F; Colombo P; Bettini R; Barchielli M; Leoni B; Loprete L; Rossi A
    J Control Release; 2017 Sep; 262():296-304. PubMed ID: 28774840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of flurbiprofen in the fed and fasted states.
    Dressman JB; Berardi RR; Elta GH; Gray TM; Montgomery PA; Lau HS; Pelekoudas KL; Szpunar GJ; Wagner JG
    Pharm Res; 1992 Jul; 9(7):901-7. PubMed ID: 1438004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability and pharmacokinetics of two oral formulations of flurbiprofen: a single-dose, randomized, open-label, two-period, crossover study in Pakistani subjects.
    Qayyum A; Najmi MH; Abbas M
    Pak J Pharm Sci; 2013 Nov; 26(6):1221-7. PubMed ID: 24191330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil.
    Charoo NA; Shamsher AA; Kohli K; Pillai K; Rahman Z
    Colloids Surf B Biointerfaces; 2008 Sep; 65(2):300-7. PubMed ID: 18579348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced solubility and bioavailability of flurbiprofen by cycloamylose.
    Baek HH; Kwon SY; Rho SJ; Lee WS; Yang HJ; Hah JM; Choi HG; Kim YR; Yong CS
    Arch Pharm Res; 2011 Mar; 34(3):391-7. PubMed ID: 21547670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of flurbiprofen in man. II. Plasma protein binding.
    Szpunar GJ; Albert KS; Wagner JG
    Res Commun Chem Pathol Pharmacol; 1989 Apr; 64(1):17-30. PubMed ID: 2749000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.